BioCentury
ARTICLE | Company News

Depomed, Actavis neurology news

May 4, 2015 7:00 AM UTC

The companies resolved patent litigation related to Depomed’s Gralise gabapentin. Under the settlement, Actavis admits that all seven patents owned by Depomed covering Gralise are valid and enforceable and would be infringed by Actavis’ proposed generic. The patents expire between 2016 and February 2024, but Depomed granted Actavis a license to launch a generic in the U.S. by Jan. 1, 2024. The settlement resolves Actavis’ pending appeal filed in the U.S. Court of Appeals for the Federal Circuit after the U.S. District Court for the District of New Jersey ruled in favor of Depomed (see BioCentury, Sept. 8, 2014). ...